Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) commences share repurchases on June 25, 2021, under the program mandated by the shareholders in the Annual General Meeting held on June 2, 2021. As per the mandate, the company is authorized to repurchase its own shares.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.36 CNY | +3.09% | +0.20% | -9.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.75% | 3.15B | |
+35.04% | 5.92B | |
-15.13% | 4.51B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B | |
+33.40% | 1.38B |
- Stock Market
- Equities
- 600535 Stock
- News Tasly Pharmaceutical Group Co., Ltd
- Tasly Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan, under the authorization approved on June 2, 2021.